AstraZeneca Streamlines Portfolio with Four More Externalisation Deals
By Keshav Mahawar
Pharma Deals Review: Vol 2016 Issue 10 (Table of Contents)
Published: 21 Oct-2016
DOI: 10.3833/pdr.v2016.i10.2203 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Continuing its strategy of offloading non-core products in order to prioritise its resources on key growth areas, AstraZeneca (AZ) has out-licensed its Phase IIb inflammatory disease asset MEDI2070 to Allergan and granted Insmed global rights to Phase II-ready AZD7986 for non-cystic fibrosis bronchiectasis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS